Story perspectives

New Trials Aim to Treat Frontotemporal Dementia Variants

10/31/2025

Summary

Passage Bio Advances Dementia Therapy

Passage Bio Inc. announced on October 24, 2025 a study to evaluate safety and efficacy for frontotemporal dementia linked to granulin gene (GRN) or C9ORF72 mutations.
AL001 is being developed by Alector in collaboration with GlaxoSmithKline (GSK).
AVB-101 is a gene therapy in Phase I/II trials that aims to restore progranulin levels through a minimally invasive procedure.

Summary

Samsung Innovates Dementia Prediction

Researchers at Samsung Medical Center developed the optimized polygenic risk score (optPRS) to predict Alzheimer's disease risk.
Using data from over 1,600 Korean patients, optPRS associates higher scores with double the risk of developing dementia.
Richard Oakley of the Alzheimer's Society (UK) emphasizes dementia is preventable through lifestyle changes.
About 45% of dementia cases could be avoided by addressing modifiable risk factors such as diet, exercise, and education.

1 of 2

Passage Bio Advances Dementia Therapy

Passage Bio Inc. announced on October 24, 2025 a study to evaluate safety and efficacy for frontotemporal dementia linked to granulin gene (GRN) or C9ORF72 mutations.
AL001 is being developed by Alector in collaboration with GlaxoSmithKline (GSK).
AVB-101 is a gene therapy in Phase I/II trials that aims to restore progranulin levels through a minimally invasive procedure.

1 / 2